GlaxoSmithKline Licenses Computable Biological Knowledge Base


Mountain View, California, September 22, 2003 – Ingenuity Systems announced today that GlaxoSmithKline (NYSE: GSK) has licensed part of the Ingenuity Pathways Knowledge Base to aid their internal development efforts of genome-scale computational solutions for better understanding of biological systems underlying disease.

The Ingenuity Pathways Knowledge Base is a curated database of biological networks created from millions of individually modeled relationships between proteins, genes, complexes, cells, tissues, drugs, and diseases. This product is distinctive in its unrivaled computational capabilities enabled through its highly structured ontology, unsurpassed quality of data, and genome-scale coverage.

The Ingenuity Pathways Knowledge Base is available for license by pharmaceutical and biotechnology companies. informatics groups focused on increasing R&D productivity through the application of innovative solutions. By helping bioinformaticians and researchers systematically analyze their experimental data in the context of biological pathways, the Ingenuity Pathways Knowledge Base provides value throughout the drug discovery process, from early stage target ID and validation, to later stage activities such as toxicology, pharmacogenomics, biomarker identification, and alternative indications of approved drugs.

The Ingenuity Pathways Knowledge Base powers other computational solutions that Ingenuity offers such as the IPA application, a turnkey web-delivered solution.

Informatics professionals who are interested in learning more about the Ingenuity Pathways Knowledge Base product should contact us.

About Ingenuity Systems

Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View,